Results 1 to 10 of about 4,279 (197)

Dalbavancin. [PDF]

CMAJ
Stevenson IR, Bai AD, Shchepanik K.
europepmc   +14 more sources

Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience [PDF]

Antibiotics, 2023
Dalbavancin is a long-acting lipoglycopeptide that is registered for the treatment of acute bacterial skin and skin structure infections, and it is also increasingly used for infections that require prolonged antibiotic treatment.
Dario Cattaneo, Marta Fusi, Marta Colaneri, Chiara Fusetti, Camilla Genovese, Riccardo Giorgi, Maddalena Matone, Stefania Merli, Francesco Petri, Andrea Gori   +9 more
doaj   +3 more sources

In vitro additive effects of dalbavancin and rifampicin against biofilm of Staphylococcus aureus [PDF]

Scientific Reports, 2021
Dalbavancin is a novel glycopeptide antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). It is characterized by a potent activity against numerous Gram-positive pathogens, a long elimination half-life and
Benjamin Jacob, Oliwia Makarewicz, Anita Hartung, Steffen Brodt, Eric Roehner, Georg Matziolis   +5 more
doaj   +2 more sources

Determination of a Tentative Epidemiological Cut-Off Value (ECOFF) for Dalbavancin and Enterococcus faecium [PDF]

Antibiotics, 2021
Dalbavancin is a lipoglycopeptide antibiotic that shows potent activity against Gram-positive bacteria. It circumvents vanB-type glycopeptide resistance mechanisms; however, data on the in vitro activity of dalbavancin for Enterococcus faecium (E ...
Robert E. Weber, Carola Fleige, Franziska Layer, Bernd Neumann, Michael Kresken, Guido Werner   +5 more
doaj   +3 more sources

Dalbavancin as Suppressive Therapy for Implant-Associated Osteoarticular Infections [PDF]

Antibiotics
Introduction: Suppressive antibiotic therapy (SAT) is a therapeutic alternative for complex infections where a cure is considered unlikely or impossible. SAT involves the prolonged, often indefinite, administration of antibiotics, typically given orally,
Rosa Escudero-Sanchez, Laura Morata, Luis Buzón, Sofia de la Villa, Alicia Rico, María José Nuñez Orantos, Laura Guio Carrion, María Tasias Pitarch, Jose Luis del Pozo, José M. Barbero, Joan Gómez-Junyent, María José García Pais, Pablo Bachiller Luque, Francisco Javier Martínez Marcos, Javier Cobo, GEIO (Spanish Group for Osteoarticular Infections)   +15 more
doaj   +2 more sources

Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections

Infectious Diseases and Therapy, 2019
Introduction Dalbavancin is approved for acute bacterial skin and skin structure infections (ABSSSIs) but offers a potential treatment option for complicated invasive gram-positive infections.
Jacqueline T Bork, Emily L Heil, Anthony Amoroso   +2 more
exaly   +3 more sources

Study of the release kinetics of dalbavancin from bone allografts [PDF]

Journal of Materials Science: Materials in Medicine
Bone infections are common and difficult to treat, and secondary bone defects, which are often observed, may require a bone allograft. In this case, the surgeon will add antibiotics (usually vancomycin) in direct contact with the bone graft during the ...
Roger Erivan, Nicolas Bourzat, Mouloud Yessaad, Guillaume Villatte, Stéphane descamps, Stéphane Boisgard, Philip Chennell   +6 more
doaj   +2 more sources

Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs

Drug Design, Development and Therapy, 2021
Milo Gatti,1,2 Massimo Andreoni,3,4 Federico Pea,1,2 Pierluigi Viale1,5 1Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy; 2SSD Clinical Pharmacology, IRCCS Azienda Ospedaliero-Universitaria di ...
Milo Gatti, Massimo Andreoni, Federico Pea   +2 more
exaly   +2 more sources

Dalbavancin [PDF]

Revista Española de Quimioterapia, 2021
Dalbavancin is a long-acting antimicrobial agent with an excellent in vitro activity against Gram-positive pathogens, including staphylococcal biofilms. The unusually long terminal half-life ranging from 149 to 250 hours in human subjects, allows a weekly dose.
Barberán, José, de la Cuerda, Alicia, Barberán, Lourdes Cristina   +2 more
  +5 more sources

Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care

Antibiotics, 2020
Introduction: Dalbavancin is an antibiotic administered by intravenous infusion weekly or bi-weekly and is currently FDA-approved only for treatment of skin and soft-tissue infections. It has shown promise, but is not considered the standard of care, for
Sarah A Schmalzle, Emily L Heil
exaly   +3 more sources